Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)

Next Previous
Trial Profile

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Carboplatin; Infliximab; Mycophenolate mofetil; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms DUO-O
  • Sponsors AstraZeneca; AstraZeneca AB; Myriad Genetic Laboratories

Most Recent Events

  • 10 Feb 2026 According to AstraZeneca media release, the company in Q4 2025 decided not to progress with regulatory filings of Lynparza in US, Europe, China or Japan, after further data follow up from this study and health authority interactions.
  • 25 Jul 2024 Planned End Date changed from 25 May 2028 to 30 Mar 2028.
  • 25 Jul 2024 Planned primary completion date changed from 28 Aug 2023 to 28 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top